|
|
Blood, 15 May 2008, Vol. 111, No. 10, pp. 4841-4851.
 Previous Article | Table of Contents | Next Article 
ASH 50TH ANNIVERSARY REVIEW
Myelodysplastic syndromes
Stephen D. Nimer1
1 Division of Hematologic Oncology and Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY
There has been a remarkable explosion of knowledge into the molecular defects that underlie the acute and chronic leukemias, leading to the introduction of targeted therapies that can block key cellular events essential for the viability of the leukemic cell. Our understanding of the pathogenesis of the myelodysplastic syndromes (MDSs) has lagged behind, at least in part, because they represent a more heterogeneous group of disorders. The significant immunologic abnormalities described in this disease, coupled with the admixture of MDS stem or progenitor cells within the myriad types of dysplastic and normal cells in the bone marrow and peripheral blood, have made it difficult to molecularly characterize and model MDS. The recent availability of several, effective (ie, FDA-approved) therapies for MDS and newly described mouse models that mimic aspects of the human disease provide an opportune moment to try to leverage this new knowledge into a better understanding of and better therapies for MDS.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. M. Stone
How I treat patients with myelodysplastic syndromes
Blood,
June 18, 2009;
113(25):
6296 - 6303.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Delhommeau, S. Dupont, V. D. Valle, C. James, S. Trannoy, A. Masse, O. Kosmider, J.-P. Le Couedic, F. Robert, A. Alberdi, et al.
Mutation in TET2 in Myeloid Cancers
N. Engl. J. Med.,
May 28, 2009;
360(22):
2289 - 2301.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Ades, S. Boehrer, T. Prebet, O. Beyne-Rauzy, L. Legros, C. Ravoet, F. Dreyfus, A. Stamatoullas, M. Pierre Chaury, J. Delaunay, et al.
Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study
Blood,
April 23, 2009;
113(17):
3947 - 3952.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Y. Follo, C. Finelli, C. Clissa, S. Mongiorgi, C. Bosi, G. Martinelli, M. Baccarani, L. Manzoli, A. M. Martelli, and L. Cocco
Phosphoinositide-Phospholipase C {beta}1 Mono-Allelic Deletion Is Associated With Myelodysplastic Syndromes Evolution Into Acute Myeloid Leukemia
J. Clin. Oncol.,
February 10, 2009;
27(5):
782 - 790.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. S. Young
Paroxysmal nocturnal hemoglobinuria and myelodysplastic sydromes: clonal expansion of PIG-A-mutant hematopoietic cells in bone marrow failure
Haematologica,
January 1, 2009;
94(1):
3 - 7.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. N. Abboud
Unlocking the dysplasia puzzle
Blood,
October 15, 2008;
112(8):
3005 - 3006.
[Full Text]
[PDF]
|
|
|
|
|
